These DEPs included several previously identified plasma CHD markers, such as neuropilin‐2, ATP‐citrate synthase (ACLY), protein S100‐A7 (S100A7), myosin regulatory light polypeptide 9 (MYL9), glucose‐6‐phosphate 1‐dehydrogenase (G6PD), serine hydroxymethyltransferase (SHMT1), coactosin‐like protein (COTL1), and plasminogen activator inhibitor 1 (SERPINE1) (Jain et al, 2004; Nembhard et al, 2017; Song et al, 2017; Ference et al, 2019; Xiong et al, 2019; Zhang et al, 2019; Tan et al, 2020; Luo et al, 2022). This evidence concerns the gene S100A7 and coronary artery disorder.